Severe malaria has many manifestations, of which coma and lactic acidosis are the best independent predictors of a fatal outcome. Most deaths from malaria occur within the first 24 h of admission, despite appropriate antimalarial chemotherapy. Adjunctive therapy for severe malaria has been seen as a way to improve survival by 'buying time' until antimalarials can act. Several adjunctive therapies have undergone clinical trials in the past 25 years but all of these trials showed worsened outcome or no benefit to patients receiving adjuncts compared with those receiving placebo. Although metabolic acidosis occurs in both hypovolaemia and malaria, the contribution of the former to the pathophysiology of severe malaria is unclear. I suggest that lactic acidosis due to malaria can be explained primarily by factors that are independent of volume depletion. Lactic acidosis in malaria can be treated safely with dichloroacetate. This intervention could prove useful as an adjunctive therapy aimed at reducing mortality rates in severe malaria.